Cediranib
Stage IV Rectal Cancer
National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Stage IV Rectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Fudan University | Phase 2 | BBB |
Floxuridine City of Hope Medical Center | Phase 2 | BBB |
Eniluracil National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Dasatinib Anne Noonan | Phase 2 | B |
View all 27 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →